SCHEMBL6449359

SCHEMBL6449359

CON=Cc1ccccc1OC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 3/20 0.57
ADRA2B P18089 3/20 0.57
ADRA2C P18825 3/20 0.57
ALDH1A1 P00352 2/20 0.49
LMNA P02545 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449354 1.00 ADRA2A (0.57) ADRA2AADRA2BADRA2CALDH1A1LMNA
SCHEMBL213165 0.81 GRIN2D (0.56) ADRA2AADRA2BADRA2CALDH1A1LMNA
SCHEMBL213164 0.81 GRIN2D (0.56) ADRA2AADRA2BADRA2CALDH1A1LMNA
SCHEMBL2161222 0.80 HPGD (0.56) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL15118571 0.80 HPGD (0.56) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL2313267 0.80 ALDH1A1 (0.50) ADRA2AADRA2BADRA2CALDH1A1LMNA
SCHEMBL2161225 0.80 HPGD (0.56) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL13988354 0.77 AR (0.49) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL5412728 0.75 ALDH1A1 (0.44) ADRA2AADRA2BADRA2CALDH1A1LMNA
SCHEMBL15614321 0.74 ADRA2A (0.43) ADRA2AADRA2BADRA2CLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1617849-A HIV integrase inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-05-18 CN disclosed
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US disclosed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US disclosed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO disclosed
EP-1467695-A2 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase ACSS2, ARSA, ASS1 ADRA2A 3477/4885ADRA2B 2279/4885ADRA2C 3968/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 ADRA2A 2537/4885ADRA2B 1282/4885ADRA2C 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.